Procalcitonin:
Clinical Applications in Critical Care
Tuesday July 28, 12:00pm – 1:00pm EST,
Teleconference and Webinar
Sponsored by BRAHMS USA Inc.
Speakers:
Eric H. Gluck, MD, JD
Director of Critical Care Services,
Swedish Covenant Hospital Professor of Medicine,
Finch University of Health Sciences/Chicago Medical School
Summary:
Early diagnosis and determination of appropriate therapy are daily challenges for physicians treating septic patients. The new Procalcitonin test, recently cleared by the FDA, can help improve accuracy of the sepsis diagnosis and the efficacy of antibiotic therapy. Procalcitonin is a protein that can act as a hormone and a cytokine. It is expressed in most tissues and is released under the stimulation of sepsis. As such, it is a sensitive biomarker for the detection of bacterial infection. The serum levels also correspond to the severity of infection and the response to treatment. When used with other clinical parameters, it can result in more appropriate application of antibiotics to patients who present with clinical signs of sepsis. Though PCT is used routinely in the diagnosis and management of sepsis in Europe, the test is relatively new to the United States. more
NEWS
- Biomarkers and Sepsis: New Tools May Aid Early Diagnosis and Treatment
July 21 Symposia - Procalcitonin:
Clinical applications
in Critical Care
July 28 Symposia - Procalcitonin:
Advances in Clinical Decision Making
June 23 Symposia - BRAHMS announces new blood test better predicts heart failure outcomes in emergency setting
- BRAHMS receives FDA clearance to market automated Procalcitonin (PCT) test
- BRAHMS Receives Final FDA Clearance for PCT
- BRAHMS / bioMerieux cooperation...
